Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
 
Register now or login to post to this thread.
  • Page:
  • 1
  • 2

Alliance Pharma (APH)     

rdotdj - 29 Aug 2006 21:50

anyone into these , they seem to have a very good write up and so I bought some !!! The interims are due Sept 13th worth. watching around that date. See Objective Capital.com or it may be Objective Capital .co.uk Try both

Andy - 24 Mar 2010 15:39 - 2 of 24

New article, click HERE

Andy - 16 Apr 2010 00:04 - 3 of 24

This is a FREE event

Proactive Investors One2One Forums

The directors of Rexahn Pharmaceuticals (AMEX: RNN), Asterand (LSE: ATD), Alliance Pharma plc (AIM: APH) and EpiStem Holdings Plc (AIM: EHP) will be presenting:

Tuesday the 20th April 2010 - Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapand wine reception. Details on the presenting companies can be found below.

This event is suitable for the following:
Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.


Register Here - http://www.sign-up.to/signup.php?fid=2015&pid=7163

If you have any problems registering or queries please email action@proactiveinvestors.com

These are superb evenings set in a wonderful environment, and afford the rare opportunity for the private investor to meet the CEO's in an informal setting.


Nearest tube stations are Green Park and Bond Street.

Andy - 27 May 2010 16:51 - 4 of 24

New article, click HERE

hangon - 16 Jan 2012 18:56 - 5 of 24

Down 9.5% today =
28p- I presume that's after the sellers cashed their Div,Cheques. No logic IMHO, still
holding.
The yield isn't fantastic, unless like me you bought when the sp was a lot less than now, effectively multiplying the yield on investment.

Today, Ann. Peacocks is to file for Administation - so some sellers are not going to make
it....however, APH (for aches and pains) appears moderately immune.

dreamcatcher - 02 Aug 2012 08:46 - 6 of 24

For immediate release
2 August 2012


ALLIANCE PHARMA PLC
("Alliance" or the "Company")


Acquisition


Alliance Pharma (LSE: APH.L - news) plc (AIM: APH), the speciality pharmaceutical company, announces that its wholly owned subsidiary Alliance Pharmaceuticals Limited has acquired the antimalarial brands PaludrineTM, AvloclorTM and SavarineTM from AstraZeneca UK Limited.


Alliance expects the acquired products to generate incremental contribution before financing costs of approximately £1.1 million per annum. Alliance is paying £4.2 million initial consideration to AstraZeneca UK Limited and may pay a further sum over the next three years, which is not expected to exceed £1.0 million, dependent on sales of the brands.


The initial consideration is being funded from existing cash and bank facilities, including a £2 million drawdown from the Group's £20 million Revolving Credit Facility ("RCF"), and any deferred consideration will be funded from future cash generation. This will bring the utilisation of the RCF to £8.5 million.


The acquired products are sold mainly in the UK and France.


Appointment of Country Managers


Alliance has recently appointed a Country Manager for France, Dr Philippe Pasdelou, who will manage the sales of the anti-malarial brands in France. Philippe has considerable experience in the pharmaceutical industry, including managing several companies in France and in other countries. He also has experience setting up a company with a similar business model to Alliance.


Alliance has also recently appointed Lars Börger as Country Manager for Germany, Switzerland and Austria. Lars has experience across a number of pharmaceutical and medical device companies, in both strategic and operational roles, and was most recently Director Licensing with Grünenthal.


The Country Managers will initially focus on securing acquisition and in-licensing opportunities in line with Alliance's strategy to expand into mainland Europe (Chicago Options: ^REURUSD - news) .

dreamcatcher - 02 Aug 2012 08:47 - 7 of 24

Chart.aspx?Provider=EODIntra&Code=APH&Si

dreamcatcher - 03 Aug 2012 17:27 - 8 of 24

http://www.proactiveinvestors.co.uk/companies/news/46358/alliance-pharma-leaps-into-europe-after-securing-three-astrazeneca-anti-malarial-brands-46358.html
On the back of today’s news broker Numis increased its target price to 32 pence from 28 pence and revised its forecasts. It is now projecting 2013 pre-tax profits half a million more than originally forecast at £10.7 million.

dreamcatcher - 19 Oct 2012 15:55 - 9 of 24

UPDATE: Alliance Pharma buys stoma care product specialist
3:40 pm by Philip Whiterow and Jamie Nimmo Broker Numis upgraded the company from ‘add’ to ‘buy’ today
--adds broker comment and share price--

Speciality pharmaceutical company Alliance Pharma (LON:APH) has snapped up stoma care product specialist Opus Group for about £9.5 mln.

Opus group sells a range of products for stoma care [colostomy, ileostomy, urostomy] including skin creams and cleansers, in the UK and Ireland and generated underlying profits of £2.1 mln on sales of £3.8 mln in the year to March.

The consideration is being funded from existing cash and bank facilities. Opus’ founders Hugh Brady and John Williams will stay on for six months until David Hope, Alliance's sales and marketing director for secondary care, takes over.

“We are very pleased to complete this second major acquisition of 2012,” said John Dawson, Alliance Pharma’s chief executive.

“Opus is an exciting business with good growth potential that matches our business well in terms of customers and business drivers. It will be immediately earnings enhancing for Alliance.”

The deal will see Alliance pay £8 mln plus the net asset value of around £1.5 mln.

It will be funded out of the company’s existing revolving cash facility (RCF). The company has now spent £16.5 mln of the £20 mln available.

Alliance’s strategy is to buy up mainly prescribed and well established branded products that need little marketing.

The company owns or licenses the rights to more than 50 pharmaceutical products. Sales are mainly prescription driven and to hospitals directly or to pharmaceutical wholesalers.

Broker Numis upgraded the company from ‘add’ to ‘buy’ today, with a target price of 37 pence, up from 32 pence.

Analyst Charles Weston forecasts revenue growth of 5% per annum for Opus.

He also believes the business will require £300,000 in additional management investment, £400,000 in related support costs and £500,000 in additional interest costs on the RCF.

Weston also forecasts a 9% uplift to earnings per share in 2013, while he adds that this will increase as debt is repaid.

The news lifted the share price by 1.5 pence or 5.4% to 29.5 pence

dreamcatcher - 22 Oct 2012 19:30 - 10 of 24

Alliance Pharma: Investec ups target from 28p to 28.7p, hold rating kept.

dreamcatcher - 24 Oct 2012 17:36 - 11 of 24

Canaccord today bumped up its target price for Alliance Pharma (LON:APH) to 34 pence from 29.5 pence and reiterated its ‘buy’ rating.

The upgrade follows the pharmaceutical firm’s acquisition of Opus Healthcare, a stoma care specialist.

“At 2.4x revenues the purchase price is at the top end of the range of recent acquisitions by Alliance, but seems reasonable given the growth potential for a low risk product lines,” said the broker.

“We expect the acquisition to be earnings enhancing from completion.”

Balerboy - 24 Oct 2012 18:02 - 12 of 24

been looking at these for a few days but not bought yet, chart says wait a bit.,.
">Chart.aspx?Provider=EODIntra&Code=APH&Si

dreamcatcher - 27 Oct 2012 13:20 - 13 of 24

Tipped in this weeks share mag. There could be likely earnings upgrades after last weeks acquisition of Opus.

dreamcatcher - 15 Jan 2013 13:58 - 14 of 24

Alliance Pharma gets more ammo for acquisition drive
1:16 pm by Philip WhiterowAlliance has £13.5mln to spend following the latest injection of funds.

Alliance Pharma's (LON:APH) expansion of its acquisition fund is a key development for the specialist pharmaceutical company, according to broker Numis.

The group today announced an additional £10mln facility with Lloyds Banking Group, taking the total facility available to the group to make purchases up to £30mln.

Alliance has used £16.5mln of the facility and has £13.5mln to spend following the latest injection of funds.

Numis said that management has executed on 23 deals over the last 14 years and continually reiterates the strength of its M&A pipeline.

If the £13.5mln was fully deployed on acquisitions through 2013 at the historical average 3 times gross profit, the broker sees up to 30% upside to its 2014 profit forecasts.

“P/E multiples in the speciality pharma/generics peer group have expanded one point to 12x over the last couple of months - we therefore increase our price target to 42p, from 37p and reiterate our buy rating,” said Numis.

Alliance also said profits will beat market forecasts for the year just ended after very strong sales of skin and eczema emollient Hydromol.

“As a result of a stronger than expected gross margin rate, pre-tax profits are expected to be slightly ahead of current market expectations,“ the specialist pharmaceutical group said.

Total revenues in 2012 will be £44.9mln, compared to £46mln in the previous year.

Sales were hit by Sanofi Pasteur’s temporary suspension of the manufacture of Immucyst in June, but Hydromol’s record performance offset some of the impact. Hydromol sales grew by 29% or £1.1 mln to £4.7 mln.

Last year’s acquisitions, Opus Group and three anti-malarial brands, performed as expected, Alliance Pharma said.

Numis also raised its 2012 profit forecast to £10.5mln, from £10.2mln, following the update.

The company’s business model is to acquire the rights to established niche pharmaceutical products. It now owns or licenses the rights to more than 60 products.

Shares rose by 4% to 33.5p.

dreamcatcher - 15 Jan 2013 14:19 - 15 of 24

Had a good run since Aug, sold my holding.

goldfinger - 11 Feb 2013 09:03 - 16 of 24

Gone long this morning.

Results next month looks an interesting company.

goldfinger - 13 Feb 2013 09:03 - 17 of 24

APH

Not far off breaking out.

BUY placed on it by SCSW tip sheet
this weekend.

Personaly Im looking for a bolt on
before results on 21st of March...

see historical item below.....

Alliance Pharma gets more ammo for acquisition drive
15th Jan 2013, 1:16 pm by Philip Whiterow

Alliance has £13.5mln to spend following the latest injection of funds. Alliance Pharma's (LON:APH) expansion of its acquisition fund is a key development for the specialist pharmaceutical company, according to broker Numis.

The group today announced an additional £10mln facility with Lloyds Banking Group, taking the total facility available to the group to make purchases up to £30mln.

Alliance has used £16.5mln of the facility and has £13.5mln to spend following the latest injection of funds.

Numis said that management has executed on 23 deals over the last 14 years and continually reiterates the strength of its M&A pipeline.

If the £13.5mln was fully deployed on acquisitions through 2013 at the historical average 3 times gross profit, the broker sees up to 30% upside to its 2014 profit forecasts.

“P/E multiples in the speciality pharma/generics peer group have expanded one point to 12x over the last couple of months - we therefore increase our price target to 42p, from 37p and reiterate our buy rating,” said Numis.

Alliance also said profits will beat market forecasts for the year just ended after very strong sales of skin and eczema emollient Hydromol.

“As a result of a stronger than expected gross margin rate, pre-tax profits are expected to be slightly ahead of current market expectations,“ the specialist pharmaceutical group said.

Total revenues in 2012 will be £44.9mln, compared to £46mln in the previous year.

Sales were hit by Sanofi Pasteur’s temporary suspension of the manufacture of Immucyst in June, but Hydromol’s record performance offset some of the impact. Hydromol sales grew by 29% or £1.1 mln to £4.7 mln.

Last year’s acquisitions, Opus Group and three anti-malarial brands, performed as expected, Alliance Pharma said.

Numis also raised its 2012 profit forecast to £10.5mln, from £10.2mln, following the update.

The company’s business model is to acquire the rights to established niche pharmaceutical products. It now owns or licenses the rights to more than 60 products.

Shares rose by 4% to 33.5p.

http://www.proactiveinvestors.co.uk/companies/news/52444/alliance-pharma-gets-more-ammo-for-acquisition-drive-52444.html

goldfinger - 15 Mar 2013 09:24 - 18 of 24

APH Alliance Pharma. Results on the 21st of this month. Thursday. Think profits will beat broker forecasts.. just added.

goldfinger - 21 Mar 2013 02:06 - 19 of 24

Results later this morning.

goldfinger - 21 Mar 2013 07:56 - 20 of 24

Solid looking results.

Finncap were looking for EPS of 3p
this year 2012 and 3.6p year ending
2013 therefore company are 1 year ahead
on expected profits.

Dividend risen aswel 10%...excelent news.

http://www.investegate.co.uk/alliance-pharma-plc--aph-/rns/preliminary-results/201303210700265097A/

Energeticbacker - 02 Feb 2015 17:23 - 21 of 24

Alliance Pharma: interesting little acquisition of a product that could be in growing demand from the ageing population - See more at: http://www.investorschampion.com/blog
  • Page:
  • 1
  • 2
Register now or login to post to this thread.